Author

H. L. Hammond

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:mouse· 3 Research Focus:host-pathogen & immune response· 2 Assay:proteomics· 2 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Assay:protein structure· 1

Frequent Co-Authors

C. Dillen· 3 shared R. M. Johnson· 3 shared S. M. Weston· 3 shared A. Chang· 2 shared A. G. Schmidt· 2 shared A. Ozonoff· 2 shared A. Z. Xu· 2 shared B. M. Hauser· 2 shared

Activity by Year

2021-2021 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

C. Dillen

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Phage-like particle vaccines are highly immunogenic and protect against pathogenic coronavirus infection and disease

B. J. Davenport, A. Catala, S. M. Weston, R. M. Johnson, J. Ardunay, H. L. Hammond, C. Dillen, M. B. Frieman, C. E. Catalano, T. E. Morrison

This paper develops a phage-like particle vaccine platform that is immunogenic and protects against SARS-CoV-2 and MERS-CoV infection and disease.

bioRxiv · Nov 8, 2021Immunology

An adjuvanted SARS-CoV-2 RBD nanoparticle elicits neutralizing antibodies and fully protective immunity in aged mice

F. Borriello, E. Nanishi, H.-S. Seo, T. R. OMeara, M. E. McGrath, Y. Saito, R. E. Haupt, J. Chen, J. Diray-Arce, K. Song, A. Z. Xu, T. M. Caradonna, J. Feldman, B. M. Hauser, A. G. Schmidt, , O. Levy

This study identifies an adjuvanted SARS-CoV-2 RBD nanoparticle that induces neutralizing antibodies and full protection in aged mice.

bioRxiv · Sep 9, 2021 · PreprintImmunology

Alum:CpG adjuvant enables SARS-CoV-2 RBD-induced protection in aged mice and synergistic activation of human elder type 1 immunity

E. Nanishi, F. Borriello, T. R. O'Meara, M. E. McGrath, Y. Saito, R. E. Haupt, H.-S. Seo, S. D. van Haren, B. Brook, J. Chen, J. Diray-Arce, S. Doss-Gollin, M. De Leon, K. Chew, M. Menon, , D. J. Dowling

This study evaluates AH:CpG adjuvant's ability to enhance RBD vaccine efficacy in aged mice and human elder cells, showing strong neutralizing antibody responses and cytokine production.

bioRxiv · May 20, 2021Immunology